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Objective: The 2002 Cystic Fibrosis Foundation (CFF) practice guidelines recommend adjusting for genetic potential when evaluating height
status in children with CF. However, there is paucity of data to support this recommendation. We compared three methods of classifying short
stature: unadjusted height percentile b10th, Himes adjusted height percentile b10th, and unadjusted height below the CFF target height lower
bound.
Patients and methods: Data from 3306 children with parental heights documented in the 1986–2005 CFF Patient Registry were analyzed.
Results:Mean height percentile of CF children (33rd) was lower than their parents' (mothers' 53rd, fathers' 57th), and 80% of CF children were below
the average of their parental height percentiles. In children with short parents, Himes adjusted height percentile was significantly higher than unadjusted
height percentile (27th vs. 8th), whereas the opposite was found in children with tall parents (Himes adjusted at 18th vs. unadjusted at 49th).
Consequently, the prevalence of short stature decreased from 52% to 22% in children with short parents and increased from 8% to 34% in children with
tall parents after Himes adjustment. In childrenwith discrepant classification on short stature before and afterHimes adjustment, percent predicted forced
expiratory volume in one second was negatively associated with unadjusted height percentile but positively associated with Himes adjusted height
percentile. In children with short parents, the CFF method underestimated the prevalence of short stature (9%) compared to the Himes method (22%).
Conclusion: Without adjustment of genetic potential, the prevalence of short stature is underestimated and the association between height and lung
function is biased.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Height; Parent–child relationship; Short stature; Lung function1. Introduction
Height is both a hereditable trait and a feature of growth that is
profoundly impacted by nutrition and disease. It is important that
the genetic contribution to height be considered when evaluatingAbbreviations: CF, Cystic fibrosis; CFF, Cystic Fibrosis Foundation; FEV1,
Forced expiratory volume in one second.
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doi:10.1016/j.jcf.2010.01.003the influence of nutrition and disease on attained height, especially
for children with chronic diseases such as cystic fibrosis (CF).
According to the 2004 Cystic Fibrosis Foundation (CFF) Patient
Registry Annual Report, 15% of CF children had heights below
the 5th percentile without adjusting for their genetic potential [1].
The prevalence of short stature in CF children is likely to be
different if the contribution of genetic potential is accounted for.
One possibility is that the prevalence of short stature in CF
children may be overestimated, because parents of CF patients
may be shorter than normal adults, as reported by a recent Italian
study [2]. Alternatively, the prevalence of short stature in CF
childrenwould be underestimated if their parents have normal/tall
stature, as revealed in our previous analysis using data from ad by Elsevier B.V. All rights reserved.
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the effects of genetic potential versus disease impact in order to
provide optimal clinical care.
The genetic potential for height is commonly estimated from
parental stature.However,methods for utilizing parental stature to
adjust the child's stature vary [4–10]. The 2002 CFF consensus
report [10] recommended a simple method to estimate genetic
potential, namely, calculation of target height range based on
parental heights, when evaluating height status in children with
CF [7]. The concept of this method is that a healthy and well-
nourished child's attained adult height shall reflect his/her genetic
potential. The CFF target height method [7,10] is intuitive to
interpret and convenient to use, but has not been validated in
the CF population. Clinical applications also reveal limited use
because the CFF target height range is very large (e.g., for boys,
176±10 cm spans the 7th to the 93rd percentile on the CDC
growth chart, ref [11]). This means that even if a child's height is
substantially below the target height, he/she most likely would
remain above the lower bound of the target height range and thus
be considered as meeting his/her genetic potential.
Another method, developed by Himes et al. [8], also utilizes
parental heights to adjust the child's height. This method [8]
is based on statistical modeling of age-specific relationships be-
tween mid-parental heights and children's heights using data from
the Fels Longitudinal Study [12]. Nevertheless, Himes method [8]
requires the use of large reference tables to calculate an “adjusted
height”, making it impractical for use in routine clinical settings.
The objectives of this study are to utilize the 1986–2005 CFF
Patient Registry to: 1) compare the difference between unadjusted
height to Himes adjusted height percentiles [8] and their
associations to lung function, and 2) examine the agreement
between the CFF target height method [7,10] and the Himes
adjusted height method [8] in classifying short stature.
2. Subjects and methods
2.1. Study population
TheCFFPatient Registry documents the diagnosis and follow-
up evaluations of patients with CF who are seen at accredited
centers in the United States [13]. Data from 3510 children older
than 2 years of age who had self-reported parental heights
available were identified from the 1986–2005 CFF Patient
Registry. Of these, 204 patients with parental heights less than
100 cm (likely due to inch–centimeter conversion or recording
errors) were excluded from analysis. The most recent height
measurement between age 2 to 18.5 years for each patient was
used for analysis. Sex- and age-specific percentiles and Z-scores
for height were calculated by using the reference values from
2000 CDC growth charts [11].
2.2. The CFF target height method
This method [7,10] uses parental heights to predict the genetic
potential for a child's adult height, referred as the target height,
which is calculated bymid-parental height plus 6.5 cm for boys or
mid-parental height minus 6.5 cm for girls. A 10 cm-range above(upper bound) and below (lower bound) the target height for boys
(9 cm for girls) is then applied to define the range of normal
variation for target height. If the child's height is below the lower
bound of his/her target height, he/she is considered to be below
genetic potential. The procedure to calculate the CFF target
height and range [7,10] is described in detail in Appendix A. In
an example illustrated in Fig. 1, the child's CFF target height is
166.5 cm (7th percentile), with a lower bound at 156.5 cm (0.2th
percentile). His unadjusted height at age 15 (5th percentile) is
above his target height lower bound (0.2th percentile) and there-
fore he is meeting his genetic potential.
2.3. The Himes adjusted height method
This method [8] does not directly predict the child's genetic
potential for height. Instead, it attempts to eliminate the influence
of tall and short parental stature on the child's stature by gen-
erating an “adjusted height”, which represents the child's height
as if his/her parents had average stature. Therefore, Himes
adjusted height presumably reflects the impact of nutrition and
disease on the child's height. The procedure to calculate Himes
adjusted height [8] is described in detail in Appendix A. In the
example illustrated in Fig. 1, Himes adjusted height percentile is
22nd. If 10th percentile were used to define short stature, this boy
would be classified as “short” by unadjusted height percentile
(5th) but “normal” by Himes adjusted height percentile (22nd).
2.4. Assessment of agreement between the CFF method and the
Himes method
Direct comparisons between the CFF [7,10] and the Himes [8]
methods are not possible because the CFF method does not give
an adjusted height. Since our purpose of utilizing a parental height
adjustment method is to identify short stature, it is logical to
compare the CFF [7,10] and the Himes [8] methods based on their
agreement in classifying short stature. When we compared the
CFF lower bounds with the 2000 CDC growth charts reference
values at age 20, we found that 10 (9) cm lower bound cor-
responds to the 7th percentile cutoff point, when target height at
age 20 is at the population mean, i.e., 50th percentile. Therefore,
we applied two cutoffs, b5th and b10th, to Himes adjusted
percentile [8] to define short stature and compared each of these
two cutoffs to the CFF target height lower bound [7,10].
2.5. Association of height percentile to lung function
The associations of unadjusted height and Himes adjusted
height [8] to the lung function parameter, percent predicted forced
expiratory volume in one second (%FEV1), were evaluated. %
FEV1 was calculated according to the Wang equations [14]. For
this analysis, only patients older than 6 years of age and having%
FEV1 data were included.
2.6. Statistical analysis
Statistical analyseswere performed by using SAS (version 9.13,
SAS Institute, Inc, Cary, NC) and R (http://www.r-project.org).
Fig. 1. An example illustrating unadjusted height, Himes adjusted height, and the CFF target height and lower bound for a 15 year-old boy with unadjusted height of
157 cm (= 5th percentile) and mid-parental height of 160 cm.
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bles and by chi-square tests for proportions. All analyses involving
height percentiles were performed on the basis of Z-scores but
reported as percentiles because the latter are displayed on the 2000
CDC growth chart [11] and more commonly used in routine
clinical setting.
Agreement between any two of the three methods (unadjusted
height, CFF target height range, Himes adjusted height) in
classifying short stature was assessed by kappa statistic [15,16]. A
kappa of b0.4 is considered “poor” agreement, between 0.4 and
0.6 “fair” agreement, between 0.6 and 0.8 “moderate” agreement,
and N0.8 “good” agreement.
3. Results
3.1. Height status of CF children and their parents
Table 1 shows that, in our study population, CF children were
shorter than normal children (mean height percentile at 33rd),
but their mothers (164.1 cm, 53rd percentile calculated based on
the CDC 2000 growth charts at age 20 years) and fathers
(178.4 cm, 57th percentile) were slightly taller than the normal
population (176.5 cm for adult men and 162.3 cm for adult
women, ref [17]). Consistent with these results, mean height
percentile of CF children was below the average of their parental
height percentiles (i.e., 55th) by an average of 22 percentile
points, and 80% of CF children were below the average of theirparental height percentiles (Table 1). Two-thirds of children had
“average” parents (mean of parental height percentiles between
26th and 74th), 22% had “tall” parents (mean of parental height
percentiles ≥75th), and 11% had “short” parents (mean of
parental height percentiles ≤25th).
3.2. Comparison between unadjusted height and Himes adjusted
height
As shown in Fig. 2, overall mean unadjusted height percentile
(27th) was significantly higher than Himes adjusted height
percentile (21st), pb0.0001. The difference between unadjusted
and Himes adjusted height percentiles varied greatly by parental
stature. Among children with average parents, small differences
were found between unadjusted and Himes adjusted height
percentiles. However, among children with short parents, Himes
adjusted height percentiles were substantially higher than
unadjusted height percentile (27th vs. 8th, pb0.0001), while
the opposite was found among children with tall parents (18th
vs. 49th, pb0.0001).
Differences between unadjusted and Himes adjusted height
percentiles led to different prevalence estimates of short stature.
The prevalence of short stature determined by Himes adjusted
height b10th percentile was 5% higher compared to that
determined by unadjusted height b10th percentile (Table 2).
However, this does not fully reflect the discrepancy between these
two methods, because Himes method increased the prevalence of
Table 1
Height status of children with CF and their parents.




CF children's most recent height measurement
Percentile 33±28
Z-score −0.62±1.08








Percentile (at age 20 on the 2000 CDC growth chart) 57±30
Z-score 0.22±1.10
Average parental height percentile 55±23
Average of parental height Z-scores 0.17±0.85
Child's height percentile minus average parental height percentile −22±27
Number (percentage) of children with height percentile below their
average parental height percentiles
2631 (80%)
Number (percentage) of children with
Short parents (average parental height percentiles ≤25th) 388 (11%)
Average parents (average parental height percentiles 26th–74th) 2204 (67%)
Tall parents (average parental height percentiles ≥75th) 714 (22%)
Data from 1986 to 2005 CF Foundation Patient Registry.
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but decreased it among children with short parents (from 52% to
22%), Table 2. Consequently, 30% of children who had short
parents and 26% of children who had tall parents had discrepant
classification on normal vs. short stature comparing these two
methods (Fig. 3).
3.3. Impact of discrepancy between unadjusted and Himes
adjusted height on their associations to lung function
The subgroup of children with discrepant classification
between unadjusted height b10th percentile and Himes adjusted
height b10th percentile were examined. As shown in Fig. 4, the
association of height to %FEV1 at age 15 (n=217) changed from
negative (regression coefficient −5.5% and correlation coeffi-
cient −0.11, panel A) when unadjusted height was used to
positive (regression coefficient +7.3% and correlation coeffi-
cient 0.14, panel B) when Himes adjusted height was used,
p=0.04. This is because, in children who were classified as short
by unadjusted method but normal by Himes method (primarily
because their parents were short), unadjusted height percentiles
were lowwhile Himes adjusted height percentiles were high (red
points in Fig. 4). In contrast, in children who were classified as
normal by unadjusted method but short by Himes method
(primarily because their parents were tall), unadjusted height
percentiles were high while Himes adjusted height percentiles
were low (blue points in Fig. 4). Similar results were observed at
age 10 (n=334), 17 (n=164) and 18 (n=128) years (data not
shown). Taken together, these results indicate that unadjusted
height percentiles masked the association between height and
lung function in children with short and tall parents.3.4. Comparison of the CFF method to the Himes method in
classifying short stature
The CFF method classified significantly fewer children with
short stature than Himes adjusted height b10th percentile, but
more children with short stature than Himes adjusted height
b5th percentile (Table 2). More importantly, the differences in
the prevalence of short stature between the Himes method and
the CFFmethod were much greater among children with short or
tall parents (Table 2). It should be noted that, even if we choose a
cutoff for the Himes method that matches exactly to the CFF
lower bound for average parents (i.e., 7th percentile), these two
methods still would not agree in children who have tall or short
parents (data not shown). This is because the CFF lower bound
values are fixed and chosen based on a confidence interval
centered around the population mean; these lower bound values
are too large for children with short parents. Consistent with
these findings, the disagreement between the CFF method and
Himes method was also largest among CF children who had
short parents (Fig. 3).
4. Discussion
A recent study from an Italian population reported for the first
time that young CF adults are shorter than their healthy peers
because their parents are also short [2]. CF children in our study
population are also short, but their parental statures are similar
to normal adults (Table 1). One possible explanation for this
discrepant observation is the difference in sample size. In the
Italian study [2], sample size of the CF patients/parents was not
reported, thus it's unclear whether that sample is representative
of the entire Italian CF population. One the other hand, our study
included a large sample size drawn from the CF Foundation
Patient Registry of the US.
Two findings from our study support the importance of
accounting for genetic potential when evaluating stature in
children with CF. First, the overall prevalence of short stature in
our study population, regardless of what cutoff point is used, is
underestimated without adjustment for genetic potential. This is
because the majority of CF children's height percentiles are lower
than those predicted based on their parental heights, most likely
due to malnutrition associated with CF. Therefore, the overall
distribution of CF children's heights is likely to shift toward
shorter stature,when compared to the distribution of the heights of
their parents, who do not have CF. Consequently, CF children's
height distribution is likely to differ before and after adjusting for
genetic potential/parental height, which supports the need for
such adjustment. Most importantly, without adjusting for parental
heights, the prevalence of short stature in children with short
parents is overestimated while prevalence of short stature in
children with tall parents is underestimated (Table 2).
Second, our study demonstrated that adjustment for genetic
potential based on theHimesmethod [8] changed the direction the
association between height and lung function. To our knowledge,
this is a novel finding. Our analysis showed that, in CF children
who had discrepant classification before and after Himes
adjustment, unadjusted height percentile is negatively associated
Fig. 2. Comparison of unadjusted height percentiles and Himes adjusted height percentiles in children with CF. Short parents: average parental height percentiles
≤25th; average parents: average parental height percentiles between 26th and 74th; tall parents: average parental height percentiles ≥75th.
Table 2
Comparison of the prevalence of short stature defined by different methods.







No. of CF children 3306 388 2204 714
Prevalence of short stature defined by
Unadjusted height percentile b5th 16%b 35%b 16%b 4%b
Unadjusted height percentile b10th 26%b 52%b 27%b 8%b
Himes adjusted height percentile b5th 18%b 13%b 18%b 22%b
Himes adjusted height percentile b10th 31%b 22%b 32%b 34%
CFF lower bound method 24% 9% 23% 39%
a Short parents: average of mother's and father's height percentiles ≤25th.
Average parents: average of mother's and father's height percentiles between
26th and 74th. Tall parents: average of mother's and father's height ≥75th.
b pb0.05, pair-wise comparison to the CFF lower bound method.
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discovery that Himes adjusted height percentile is positively
associated with %FEV1 uncovered the underlying explanation to
this contradiction. It should be emphasized that, without adjust-
ment of genetic potential, the positive association between height
and lung function would not only vanish but also a negative
association would appear.
Several implications can be drawn from the above findings. At
the individual patient's level, unadjusted height masks the true
impact of CF-associated malnutrition on linear growth. That is,
unadjusted height percentile is likely to misclassify a CF child
with tall parents to be “normal stature” and a CF child with short
parents to be “short stature”. Therefore, treatment decisions based
on unadjusted height may be misguided. A negative association
between unadjusted height percentile and lung function may
also mislead CF clinicians that improving height status would
have little impact on lung function. This finding needs to be
validated with other measures of pulmonary status such as chest
radiography.At the population level, the difference in prevalence estimates
between using unadjusted and Himes adjusted height percentile
for classifying short stature is large enough to be of concern,
Fig. 4. Comparison between unadjusted height percentile (panel A) and Himes
adjusted height percentile (panelB) on their associations to lung function parameter
percent predicted forced expiratory volume in one second (%FEV1) in CF children
with discrepant classification on short stature at age 15 (n=217).
Fig. 3. Pair-wise comparisons of the discrepancy among four methods of deter-
mining the prevalence of short stature in CF children. Short parents: average parental
height percentiles ≤25th; average parents: average parental height percentiles
between 26th and 74th; tall parents: average parental height percentiles ≥75th.
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CFF's nutrition outcome measure [3,10,18] that is used as an
indicator to monitor treatment progress over time in the national
CF population, as well as for comparison of center differences
[18–20]. In addition, quality improvement projects implemented
bymanyCF centers often aim at reducing the rates ofmalnutrition
that are defined not only by weight but also height status of CF
children [18,21].
Based on the above evidence, it is essential to account for
genetic potential when evaluating height status of CF children.
However, we showed that current methods in use, namely, the
CFF target heightmethod [7,10] and theHimesmethod [8], do not
agree. In addition, both methods have disadvantages. The CFF
method [7,10] is easy to understand and use, but the target height
lower bounds are invalid, particularly for children who have short
parents. The Himes adjusted height method [8], although not a
gold standard either, is more accurate because it is derived based
on observed relationships between parent and child statures.
Nevertheless, Himes method [8] is complicated and inconvenient
to use in routine clinical settings. A new method, one that retains
the simplicity of theCFFmethod [10] but agreeswith the accuracy
of the Himes method [8] is needed.
One weakness in our study is that, unlike the Italian study
[2] in which parental height was measured, parental heights
were self-reported. Our results show that CF children's parents
are slightly taller than the normal population. This observation
may be reflective of the higher proportion of white and black
races (98%) compared to the general US population (93%
white and black races, ref [22]) and/or due to self-reporting
bias. According to data from US population survey, adults
over-reported their heights by an average of 1.22 cm in men
and 0.68 cm in women [17]. When we subtracted these average
over-reported values, mean mothers' and fathers' heights
became almost the same as the normal population mean (52nd
and 51st percentile for fathers and mothers, respectively).
Nevertheless, the discrepancy between the CFF method [7,10]
and the Himes method [8] in classifying short stature observed
in our study remains present after accounting for potential
over-reporting of parental heights.
An area of uncertaintywith regard to usingmid-parental height
to determine a child's target height is thatmid-parental heightmay
not be a good predictor for children with discordant parents, i.e.,
tall father and short mother or vice versa, because the genetic
contribution to a child's stature may be unequal from each parent.
Further research is needed to develop appropriate methods to
adjust for genetic potential in children with discordant parents. In
fact, the questions that need to be addressed first are what is the
definition of discordant parents, and is it necessary to develop
different methods for this population? Himes method [8] assumes
equal genetic contribution from each parent, with no dominance
effect, which agrees with other evidence [23]. Pubertal growth is
another area concern for using mid-parental height to adjust
genetic potential. Evidence shows that the relationship between
mid-parental height and child's height changes during pubertal
growth [23], most likely due to large individual variations in the
timing of pubertal growth spurt. Methods for adjusting genetic
potential, aswith anymethod to evaluate nutritional status, should
141Z. Zhang et al. / Journal of Cystic Fibrosis 9 (2010) 135–142be used in conjunction with indicators of pubertal maturation
during the adolescent period.
In conclusion, findings from the present study provide strong
evidence to support CFF's recommendation that genetic
potential must be incorporated when evaluating height status
in CF children with short or tall parents. In addition, inter-
pretation of stature with or without adjustment of genetic po-
tential requires consideration of biological maturation of the
individual child, particularly during pubertal growth. Himes
adjustment method [8] is valid, based on its methodology and
its association with lung function. On the other hand, the CFF
target height method [7,10] is inappropriate, because its fixed
lower bounds are flawed (i.e., too large for short target heights
and too small for tall target heights). Further research is needed
to develop new methods that agree with the accuracy of the
Himes method and are convenient to use in routine clinical
settings.
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Appendix A
Procedure to calculate CFF target height and range [7,10]
1. Average two parental heights to obtain mid-parental height.
Calculate the child's target adult height by adding 6.5 cm to
mid-parental height for a boy, or subtracting 6.5 cm for a girl.
Apply ±10 cm for a boy or ±9 cm for a girl to define the target
height range.
2. Plot target height and range at age 20 years on the 2000 CDC
growth chart [11] and estimate their respective percentiles.
3. Extrapolate the percentiles of target height and range at age
20 to the child's current age.
4. Plot the child's height on the 2000 CDC growth chart [11]; if
his/her height percentile is below the target height lower bound,
he/she is considered to be below genetic potential.
In the example shown in Fig. 1 (15 year-old boy, unadjusted
height=157 cm=5th percentile, mid-parental height=160 cm),
the child's CFF target height is 166.5 cm (7th percentile), with a
lower bound at 156.5 cm (0.2th percentile). His unadjusted
height percentile at age 15 (5th) is above the target height lower
bound percentile (0.2th) and therefore he is meeting his genetic
potential.
Procedure to calculate Himes adjusted height [7]
1. Calculate mid-parental height.2. Based on the child's sex, age, height and mid-parent height,
find the adjustment value from the reference tables [8].
3. Apply the adjustment value to the child's height to obtain
adjusted height.
4. Plot adjusted height on the 2000 CDC growth chart [11] to
obtain adjusted height percentile.
In the example shown in Fig. 1 (15 year-old boy, unadjusted
height=157 cm=5th percentile, mid-parental height=160 cm),
Himes adjustment value is 7 cm and Himes adjusted height is
164 cm (22nd percentile). If 10th percentile were used to define
short stature, this boy would be classified as “short” based on
unadjusted height percentile (5th) but “normal” based on Himes
adjusted height percentile (22nd).
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